University of Massachusetts Medical School

  • Post Doctoral Associate - 31795

    Minimum Salary US-MA-Worcester
    Job Location 1 month ago(10/16/2018 3:22 PM)
    Requisition Number
    2018-31795
    # of Openings
    1
    Posted Date
    Day
    Shift
    Exempt
    Exempt/Non-Exempt Status
    Non Union Position-W63-Residents/Post Docs
  • Responsibilities

    The Wolfe laboratory will be filling a postdoctoral position to develop new delivery reagents/methods for Cas9-based nucleases for somatic cell genome editing in collaboration with the Khvorova, Sontheimer and Watts labs at UMMS. This project is associated with the NIH Common Fund Somatic Cell Genome Editing program (https://commonfund.nih.gov/editing)

     

    Our experimental efforts will focus on:

     

    1) The development of new guide RNA compositions to facilitate delivery of Cas9 and Cpf1 to somatic cells.

     

    2) The development of new nuclease platforms with improved delivery and precision properties.

     

    Qualifications

    Candidates should have a Ph.D. in biology, biochemistry, chemistry or a related biomedical science. In addition, the potential candidate must have strong oral and written communication skills and be eager to present research results at national meetings. Prior experience with CRISPR-Cas9 nuclease platforms, cell culture, and deep-sequencing technologies is advantageous, but not required.

     

    Additional Information

    TO APPLY:

    Applicants should send a letter (via email) describing their current research activities and their interest in this position, a CV (including publications) and contact information for three references, including your Ph.D. advisor.

     

    Address letters to Scot Wolfe at: scot.wolfe@umassmed.edu

     

    Further details about the Wolfe laboratory and the positions that are available can be found at https://www.umassmed.edu/Wolfe-Lab/

    https://profiles.umassmed.edu/display/133161

    Options

    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed